Phase II study of bortezomib dexamethasone and high-dose melphalan in patients with relapse after high-dose melphalan with autologous stem cell support.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 17 Jun 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 17 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Sep 2007 New trial record.